DSIP
DSIP vs Melatonin: A Characterised Hormone and an Unresolved Peptide
CL
· 8 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
Melatonin and DSIP (delta sleep-inducing peptide) are both linked to sleep, but they are not comparable as evidence. Melatonin is an endogenous pineal hormone with cloned receptors, meta-analyses of randomised trials, and licensed products: in Canada it is regulated as a natural health product for adults. DSIP is a nine-residue peptide isolated in 1977 whose receptor has never been identified, whose human sleep studies are small and date from 1981 to 1992, and which is approved nowhere. No study has compared the two.

What are DSIP and melatonin?
Melatonin is a small indoleamine, N-acetyl-5-methoxytryptamine, made mainly by the pineal gland at night under the control of the suprachiasmatic nucleus, the brain's central clock. It is not a peptide. Its chemistry, synthesis and rhythm have been worked out for decades, and the broader pineal background is covered in Epithalon, melatonin and the pineal gland.
DSIP is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, characterised by Schoenenberger and Monnier from the cerebral venous blood of rabbits held in an electrically induced sleep state (PMID 265572). Its name records the hypothesis the Basel group was testing, not a property that was later confirmed. The DSIP sleep article tells that history in full.
Side by side
| Melatonin | DSIP | |
|---|---|---|
| Identity | N-acetyl-5-methoxytryptamine; an indoleamine, not a peptide | Nine-residue peptide, WAGGDASGE |
| Class | Endogenous pineal hormone | Peptide of uncertain physiological origin |
| Mechanism | Cloned G protein-coupled melatonin receptors in the suprachiasmatic nucleus and pituitary | No receptor identified; binding sites reported in cultured neurones |
| Evidence stage | Human: randomised trials and meta-analyses | Animal EEG studies; a few small human studies, 1981 to 1992 |
| Regulatory status in Canada | Natural health product for adults; prescription for sleep-related use under 18 | Not authorised for any use |
| What was measured | Sleep onset latency, total sleep time, sleep quality, jet-lag ratings | Animal sleep architecture; small insomnia and pain studies in people |
Does each one have a known receptor?
This is the single biggest difference, and most of the others follow from it.
Melatonin's receptors were cloned in 1994. Reppert and colleagues isolated a high-affinity melatonin receptor from sheep and human, a member of the G protein-coupled receptor family that inhibits adenylyl cyclase, and found its messenger RNA in the suprachiasmatic nucleus and the pituitary pars tuberalis (PMID 7946354). That gave researchers a target to assay, a mechanism to test, and a basis for drug design.
DSIP has nothing equivalent. Binding sites were reported on cultured rat brainstem neurones in 1983, but no receptor has been cloned and no signalling pathway characterised. No gene encoding the peptide has been found either, as DSIP and genetics explains. Kovalzon and Strekalova titled their 2006 review "a still unresolved riddle" (PMID 16539679). Without a target, results cannot be checked against a mechanism, and a long list of reported actions across sleep, temperature, hormones and pain has never been tied together. Why that matters is set out in how peptide receptors work.
What does the sleep evidence for melatonin show?
It shows modest, measurable effects in specific settings.
Ferracioli-Oda and colleagues pooled 19 randomised, placebo-controlled trials with 1,683 participants with primary sleep disorders. Melatonin shortened sleep onset latency by 7.06 minutes on average and lengthened total sleep time by 8.25 minutes, with a small improvement in rated sleep quality. The authors called the effects modest, smaller than those of other insomnia drugs, though they did not appear to fade with continued use (PMID 23691095). Seven minutes is real and small, and it is the kind of number that disappears from marketing.
Jet lag is the setting with the clearest signal. A Cochrane review by Herxheimer and Petrie found ten randomised trials in air travellers, airline staff or military personnel; nine found that melatonin reduced jet-lag ratings after flights crossing five or more time zones, with a number needed to treat of two. The review also noted case reports suggesting people with epilepsy or taking warfarin could come to harm, and called for systematic study of melatonin's pharmacology and for routine quality control of melatonin products (PMID 12076414).
That last point turned out to matter. An analysis at the University of Guelph of 31 melatonin supplements found content ranging from 83% below to 478% above the labelled amount, lot-to-lot variation within one product of up to 465%, and serotonin in eight products. More than 71% did not fall within 10% of their label claim (Erland and Saxena, PMID 27855744). A well-characterised molecule is not the same thing as a well-characterised product.
What does the sleep evidence for DSIP show?
Very little that can be relied on. The human record is a handful of studies: Schneider-Helmert's reports on insomnia in 1981 and 1987, a double-blind study by Bes and colleagues in 16 chronic insomniac patients in 1992 (PMID 1299794), and a pilot study in chronic pain. Participant numbers were in the tens. There is no modern randomised trial, and a search of ClinicalTrials.gov returns no registered trial of the peptide. Reviewers have proposed that some reported effects may belong to structural analogues, or to a still-unidentified DSIP-like peptide, rather than to DSIP itself (PMID 16539679).
So the two do not sit at different points on the same scale. Melatonin's effects have been measured, replicated and found to be small. DSIP's have not been established at all. How to weigh old, small and unreplicated studies is covered in the study design guide.
How is melatonin regulated in Canada, and DSIP?
Health Canada classifies melatonin generally as a natural health product. It states that melatonin is regulated as a natural health product to help promote regular sleep cycles in adults, and that all licensed melatonin natural health products are indicated for adult use only. Health Canada publishes melatonin monographs that set out what a licensed product may claim.
Children are now treated differently. One prescription drug containing melatonin, Slenyto, is authorised for insomnia in children and adolescents aged 2 to under 18 with autism spectrum disorder or Smith-Magenis syndrome. Following a consultation, Health Canada amended the Prescription Drug List with effect from 2 June 2026, so that melatonin is a prescription drug when sold for sleep-related use in people under 18 (notice of amendment). Licensed adult natural health products are unaffected.
DSIP has no Canadian authorisation of any kind: it is not a licensed natural health product and not an approved drug, and it has not been approved by the FDA or the EMA for any indication. How Health Canada's rules apply to research peptides generally is covered in what Health Canada's rules mean for research peptides.
Supplied here for laboratory use: DSIP. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
NovaEvum does not sell melatonin. Material sold here is a laboratory reagent and is not a sleep aid. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
Is DSIP a natural form of melatonin? No. Melatonin is an indoleamine made by the pineal gland from tryptophan. DSIP is a nine-residue peptide first isolated from rabbit blood. They differ in chemistry, origin and mechanism. Melatonin acts at cloned receptors; no receptor for DSIP has ever been identified.
Has DSIP ever been compared with melatonin in a trial? No. No published study has tested the two against each other, and DSIP has no registered trial of any kind on ClinicalTrials.gov. Its human sleep studies are small, date from 1981 to 1992, and were never replicated with modern methods, so there is nothing to set against melatonin's meta-analyses.
How large is melatonin's effect on sleep onset? In a meta-analysis of 19 placebo-controlled trials with 1,683 people with primary sleep disorders, melatonin shortened the time to fall asleep by about seven minutes and lengthened total sleep by about eight. The authors described the effect as modest. The jet-lag evidence, for flights crossing five or more time zones, was stronger.
Is melatonin sold over the counter for children in Canada? No. Health Canada states that all licensed melatonin natural health products are for adults. Since 2 June 2026, melatonin sold for sleep-related use in anyone under 18 is a prescription drug. One prescription product, Slenyto, is authorised for specific paediatric conditions.
Do melatonin supplements contain what the label says? Not reliably, according to one Canadian analysis. Researchers at the University of Guelph tested 31 supplements and found more than 71% fell outside 10% of the labelled content, with large lot-to-lot variation and serotonin present in eight products. Licensing sets standards; it does not guarantee every bottle.
Selected Research References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the United States of America. 1977;74(3):1282-1286. pubmed.ncbi.nlm.nih.gov/265572
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309. pubmed.ncbi.nlm.nih.gov/16539679
- Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994;13(5):1177-1185. pubmed.ncbi.nlm.nih.gov/7946354
- Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773. pubmed.ncbi.nlm.nih.gov/23691095
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews. 2002;(2):CD001520. pubmed.ncbi.nlm.nih.gov/12076414
- Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine. 2017;13(2):275-281. pubmed.ncbi.nlm.nih.gov/27855744
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. pubmed.ncbi.nlm.nih.gov/1299794
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
